Skip to main content
OpenTrials
Completed

NCT Number: NCT01679665

Systems Biology of Vaccination for EV71 Vaccine in Humans

Recently, an inactivated vaccine (vero cell) against EV71 has been investigated in Phase 1 and Phase 2 clinical trials. Data from these trials showed that the EV71 vaccine has good safety profile and was immunogenic. 320 U alum-adjuvant vaccine has been chosen as the candidate vaccine for the phase 3 clinical trial.

This clinical trial is a supplementary phase 2 trial, which is designed to study the gene expression patterns induced by EV71 vaccine in Chinese healthy children aged from 2 to 5 years old use a systems biology approach combined with microarray analysis,RT-PCR and neutralizing antibody testing for PBMC and serum collected form the studied children population, to predict immunogenicity, and explore mechanistic insights about the EV71 vaccine.

Completed

Looking for future studies?

Notify Me

Key information

Age range

2 year–5 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

Jiangsu Provincial Center for Diseases Control and Prevention

Nanjing, Jiangsu, 210009, China

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy subjects aged from 2 to 5 years old as established by medical history and clinical examination
  • The pre-vaccination neutralizing antibody against EV71 <1:8 which is determined by ELISA
  • The subjects' guardians are able to understand and sign the informed consent
  • Had never received the vaccine against EV71
  • Subjects who can and will comply with the requirements of the protocol
  • Subjects with temperature <37.1°C on axillary setting

Exclusion criteria

  • Subject who has a medical history of HFMD
  • <= 37 weeks gestation
  • Subjects with a birth weight <2.5 kg
  • Subject that has a medical history of any of the following: allergic history, or allergic to any ingredient of vaccine
  • Family history of seizures or progressive neurological disease
  • Family history of congenital or hereditary immunodeficiency
  • Severe malnutrition or dysgenopathy
  • Major congenital defects or serious chronic illness, including perinatal brain damage
  • Autoimmune disease
  • Bleeding disorder diagnosed by a doctor or significant bruising or bleeding difficulties with IM injections or blood draws
  • Any acute infections in last 7 days
  • Any prior administration of immunodepressant or corticosteroids in last 6month
  • Any prior administration of blood products in last 3 month
  • Any prior administration of other research medicines in last 1month
  • Any prior administration of attenuated live vaccine in last 28 days
  • Any prior administration of inactivated vaccines in last 14 days, such as pneumococcal vaccine
  • Under the anti - TB prevention or therapy
  • Any condition that in the opinion of the investigator, may interfere with the evaluation of study objectives

Treatment and study plan

320U /0.5ml

Biological

inactivated vaccine(vero cell) against EV71 of 320U /0.5ml, two doses, 4 weeks interval

0/0.5ml placebo

Biological

0/0.5ml placebo, two doses, 4 weeks interval

Primary outcomes

  1. Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine

    Time frame: Frame: 3 days after first dose

    Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 3 in children aged 2-5 years

  2. Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine

    Time frame: 7 days after first dose

    Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 7 in children aged 2-5 years

  3. Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine

    Time frame: 28 days after first dose

    Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 28 in children aged 2-5 years

  4. Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine

    Time frame: 28 days after second dose

    Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at day 56 in children aged 2-5 years

  5. Genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine

    Time frame: 6 months after first dose

    Identifying genomic signatures that predicted immune responses in infants vaccinated with EV71 vaccine at month 6 in children aged 2-5 years

Secondary outcomes

  1. GMT, seroconversion rate of anti-EV71 antibodies in serum after first vaccination

    Time frame: 28 days after the first vaccination

    GMT, seroconversion rate of anti-EV71 antibodies in serum 28 days after first vaccination

  2. GMT, seroconversion rate of anti-EV71 antibodies in serum after second vaccination

    Time frame: 28 days after second vaccination

    GMT, seroconversion rate of anti-EV71 antibodies in serum 28 days after second vaccination

  3. the safety of EV71 vaccine in healthy children aged 2-5 years

    Time frame: 28 days after the first dose

    Frequency of systemic and local adverse reactions within 28 days after the first dose of EV71 vaccine in healthy children aged 2-5 years

  4. the safety of EV71 vaccine in healthy children aged 2-5 years

    Time frame: 28 days after the second dose

    Frequency of systemic and local adverse reactions within 28 days after the second dose of EV71 vaccine in healthy children aged 2-5 years

Sponsors and collaborators

Lead sponsor

Jiangsu Province Centers for Disease Control and Prevention

Network

Collaborators

  • Bejing Vigoo Biological Co., LTD

Registry information

Official study title

Systems Biology of Vaccination for EV71 Vaccine in Chinese Healthy Children Aged From 2 to 5 Years Old

Important dates

Study start
2012
Primary completion
2013
Study completion
2013
First posted
Sep 6, 2012
Registry last updated
May 8, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.